Providing universal access to cancer diagnostics and early stage detection by leveraging the power of new technology.
Biomarkers play a critical role in all stages of disease. This is why rigorous evaluation is important. Analytical validation, clinical validation, and assessment of clinical utility. Each is important before the incorporation of routine clinical care. This is an important dimension of BioMark’s daily operational activity.
Rashid Ahmed Bux: BioMark Diagnostics Response to Treatment
BioMark Diagnosis Cancer Survivorship Program
Rashid Ahmed Bux: BioMark Diagnostics Screening Tool
The collective core leadership team consists of research scientists and doctors. Each with decades of diagnostic development, engineering, and biochemistry experience. Additionally, BioMark’s team consists of well experienced business professionals and leaders. The team’s goal is to drive discovery, and reduce regulatory and technical risks. We are passionate to speed up clinical adoption and work with biopharma.
Rashid Ahmed Bux, MBA – Founder, Chief Executive Officer
Dr. Jeff Haince, Ph.D – Chief Scientific Officer and GM
Dr. Bram Ramjiawan, Ph.D – Clinical Trial and Regulatory Expertise
Brian Cheng, MSc– Chief Technical Officer
Gina Huang, MBA – CFO and Project Director
Dr. Daniel Sitar – Principal Scientific Advisor / Professor Emeritus, University of Manitoba
Dr. David Wishart – Professor, Depts. of Computer Science and Biological Sciences, University of Alberta
Dr. Myron L. Weisfeldt – M.D., University Distinguished Service Professor, Professor of Medicine, The Johns Hopkins Hospital
Dr. Andrew Maksymiuk – Oncologist; Cancer Care Manitoba
Dr. Reuven Gordon – Professor, Canadian Research Chair in Nanoplasmonics, University of Victoria
Dr. Paramjit Tappia – Scientific and Clinical Researcher, St. Boniface Research Centre
Dr. John Yoo – Clinical Oncologist; Co-Chair CancerCare Ontario Head and Neck; Professor Dept. of Oncology Schulich School of Medicine & Dentistry, Western Ontario
Dr. Donald Miller – Professor, Department of Pharmacology and Therapeutics University of Manitoba
Dr. David Chen – Professor, Dept. of Chemistry, University of British Columbia
Dr. Horacio Bach – PhD, Antibody Engineering UBC
Alfred Berkeley – Strategic and financial advisor
BioMark is actively engaged in discussions with 3 high profile institutions in the US. The goal in 2022 is to accelerate clinical trials through active partnerships. The clinical trials will involve:
Miller Thomas LLP., British Columbia
Norton Rose Fulbright Canada S.E.N.C.R.L., s.r.l. / LLP, Quebec
ROBIC, LLP | LAWYERS, PATENT AND TRADEMARK AGENTS, Quebec
No paperwork, no hassle. We keep things digital, easy and regular.
*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.
1 604 370 0779
130 3851 Shell Road
Canada V6X 2W2
Rashid A. Bux (CEO)
© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.